OKYO Pharma Limited (OKYO)
| Bid | 1.25 |
| Market Cap | 42.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.43K |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | -3.29 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.26 |
| Volume | 35,978 |
| Avg. Volume (20D) | 156,815 |
| Open | 1.25 |
| Previous Close | 1.26 |
| Day's Range | 1.22 - 1.27 |
| 52-Week Range | 0.81 - 1.90 |
| Beta | -3.37 |
About OKYO
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incor...
Analyst Forecast
According to 1 analyst ratings, the average rating for OKYO stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 459.69% from the latest price.
2 weeks ago · proactiveinvestors.com
OKYO Pharma secures USAN designation ‘urcosimod' for lead assetOKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod." The company said the designation reinforces its progress in dev...
1 month ago · proactiveinvestors.com
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believeOKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it advances its lead therapeutic candidate OK-101, analysts at Goldman Small Cap Researc...
1 month ago · accessnewswire.com
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma LimitedBALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published ...
1 month ago · proactiveinvestors.com
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-endOKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for the six months ending in September 2024. The company said it expec...
1 month ago · proactiveinvestors.com
OKYO Pharma secures non-dilutive funding to advance clinical programsOKYO Pharma Ltd (NASDAQ:OKYO) has announced the receipt of $1.4 million in non-dilutive funding. The clinical-stage biopharmaceutical company is developing novel therapies for neuropathic corneal pain...